EXCLUSIVE: Enveric Biosciences Announces Non-Binding Deals To License Out Three Types of Drug Compounds [Benzinga]
Thursday, February 29, 2024 1 min read
Key Takeaway: Enveric Biosciences has entered into three non-binding term sheets with an undisclosed biotechnology company to license out three classes of drug compounds. This move aims to enhance their portfolio of neuroplasticity-promoting therapeutics for treating depression, anxiety, and addiction disorders. The agreements signify a strategic expansion for the company.
Price reaction · baseline $149.58 (2024-02-28 close) · hit pre-market · 3 other ENVB headline(s) in the window, move may be shared
day 0 close
+74.5%
day 1
+99.8%
day 3
+69.7%
Market Sentiment Analysis
POSITIVE FACTORS
Enveric Biosciences is expanding its reach through licensing agreements.
The company is focusing on innovative treatments for mental health disorders.
Non-binding deals indicate potential for future collaborations.
Full Press Release Details
Enveric Biosciences, a Florida-headquartered biotech company developing novel neuroplasticity-promoting small molecule therapeutics for depression, anxiety and addiction disorders treatment has signed three non-binding term sheets with another (undisclosed) biotechnology company toward the out-licensing of three classes of compounds.
Full Article >>
Frequently Asked Questions
What type of company is Enveric Biosciences?
Enveric Biosciences is a biotech company focused on developing therapeutics for mental health disorders.
What compounds are being licensed by Enveric Biosciences?
Enveric Biosciences is licensing out three classes of drug compounds.
Are the licensing agreements binding?
No, the agreements are non-binding term sheets.
What disorders do Enveric's therapeutics target?
The therapeutics target depression, anxiety, and addiction disorders.